Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder

Prostate

Volumn 45, Issue 2, 2000, Pages 184-193

  Beer, Tomasz ^a   Raghavan, Derek ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTHRAQUINONE DERIVATIVE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; IFOSFAMIDE; KETOCONAZOLE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISONE; TAXANE DERIVATIVE; VINBLASTINE; VINCA ALKALOID; VINDESINE; WARFARIN;

ANTIGEN DETECTION; BLOOD TOXICITY; BONE METASTASIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; CYTOTOXICITY; HORMONE DEPENDENCE; HUMAN; META ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANIMAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CYTOTOXINS; HUMAN; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033819784     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20001001)45:2<184::AID-PROS13>3.0.CO;2-K     Document Type: Review

References (93)

1. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
2. A reevaluation of non-hormonal cyctotoxic chemotherapy in the treatment of prostatic carcinoma
3. Non-hormone chemotherapy for prostate cancer: Principles of treatment and application to the testing of new drugs
4. Comparison of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in patients with advanced carcinoma of the prostate
5. A comparison of hydroxyurea, methyl-chloroethyl-cyclohexyl-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostate
6. Results of chemotherapy protocols of the US National Prostatic Cancer Project (NPCP)
7. Prostate specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
8. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy
9. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
10. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer
11. Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma
12. Treatment response criteria for prostatic cancer
13. Weekly doxorubicin in endocrine refractory carcinoma of the prostate
14. Doxorubicin, mitomycin-C and 5-fluorouracil (DMF) in the treatment of metastatic hormone refractory adenocarcinoma of the prostate with a note on the staging of metastatic prostate cancer
15. Management of hormone-resistant prostate cancer: Experience at Royal Prince Alfred Hospital
16. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
17. Health-related quality of life in men with metastatic prostate cancer treated with prednisolone alone or mitoxantrone and prednisone
18. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study
19. Science, language, intuition, and the many meanings of quality of life
20. Clinical trials in genitourinary oncology: What have they achieved?
21. Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer
22. LNCaP model of human prostatic carcinoma
23. Flow microfluorometry and transrectal fine needle biopsy in the classification of human prostatic carcinoma
24. DNA pattern and cytological findings in fine-needle aspirates of untreated prostatic tumors. A flow-cytofluorometric study
25. The biopsy and management of small cell undifferentiated carcinoma of the prostate
26. The neuroendocrine prostate: Characterization and quantitation of calcitonin in the human prostate gland
27. Chemotherapy of advanced prostate cancer
28. The significance and management of transitional cell carcinoma of the prostate
29. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment
30. Ras gene mutations in human prostate cancer
31. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate
32. An immunocytochemical analysis of TGF-β expression in benign and malignant prostatic tumors
33. Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas
34. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells
35. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas
36. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
37. Expression of the multidrug resistance gene in human prostate cancer
38. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of bcl-2 oligodeoxynucleotides
39. Evolving stategies of cytotoxic chemotherapy for advanced prostate cancer
40. Oral cyclophosphamide for the management of hormone refractory prostate cancer
41. Phase II trial of ifosfamide in the treatment of metastatic hormone refractory patients with prostatic cancer
42. Mitoxantrone: Modest activity in a phase II trial in advanced prostate cancer
43. A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II
44. Comparison of estramustine phosphate, methotrexate, and cis-platinum in patients with advanced, hormone refractory prostate cancer
45. A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area
46. A phase II trial of carboplatin in advanced prostate cancer refractory to hormonal therapy
47. Cyclophosphamide vs. cyclophosphamide, methotrexate and 5-fluorouracil in advanced prostatic cancer: A randomized trial
48. Cyclophosphamide vs. 5-fluorouracil, doxorubicin, and mitomycin C (FAM) in the treatment of hormone-resistant metastatic carcinoma of the prostate: A preliminary report of a randomized trial
49. A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma
50. Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin and methotrexate in hormone refractory prostate cancer
51. Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonists
52. Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine-HCl, in combination with various single antineoplastic agents
53. N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine in combination with cyclophosphamide: An active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer
54. Apparently increased anticancer effect in phase II trial of mitoxantrone-DPPE for symptomatic hormone-refractory prostate cancer (CAP)
55. Taxol in advanced hormone-refractory carcinoma of the prostate
56. Docetaxel (taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results
57. Phase II study of weekly docetaxel (taxotere) in hormone refractory metastatic prostate cancer (HRPC)
58. Antimicrotubule effects of estramustine, an antiprostatic tumor drug
59. Estramustine depolymerizes microtubules by binding to tubulin
60. Combined a timicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines
61. Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix
62. Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo
63. Phase II evaluation of oral estamustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate
64. A phase II trial of oral estramus tine and oral etoposide in hormone refractory prostate cancer
65. Oral estramustine and oral etoposide for hormone-refractory, prostate cancer
66. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
67. Response and preliminary survival results of a phase II study of (D) + estramustine (E) in patients (Pts) with androgen-docetaxel independent prostate cancer (AIPCA)
68. Phase I of docetaxel with estramustine in androgen-independent prostate cancer
69. Phase I/II studies of docetaxel (taxotere) combined with estramustine in men with hormone-refractory prostate cancer
70. A phase II study of docetaxel (taxotere), estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of Cancer and Leukemia Group B trial 9780
71. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (taxotere) in the treatment of hormone-refractory prostate cancer
72. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer
73. An EORTC phase II study of vindesine in advanced prostate cancer
74. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer
75. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trial
76. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer
77. Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer
78. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients
79. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial
80. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer
81. High-dose ketoconazole in advanced hormone-refractory prostate cancer: Endocrinologlc and clinical effects
82. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal
83. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer
84. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer
85. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone
86. Combined versus se quential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study
87. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone resistant prostate cancer (HRPC) based on a Canadian randomized trial (RCT) with palliative endpoints
88. A phase I study of an antisense oligonucleatide to vcl-2 (G3139, Genta) and mitoxantrone in patients with metastatic hormone refractory prostate cancer (HRPC)
89. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recur rences and 24,000 deaths among 75,000 women
90. Adjuvant therapy for patients with colon and rectal cancer
91. LNCaP model of human prostatic carcinoma
92. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results
93. Pilot study of adjuvant mitoxantrone (M) in patients (Pts) at high risk of relapse following radical prostatectomy (RP) for prostate cancer